Adimab
Private Company
Funding information not available
Overview
Adimab is a leading antibody discovery and engineering platform company that partners with biopharma organizations to advance therapeutic programs. Its core technology is a yeast-based platform that enables high-throughput screening and optimization of fully human antibodies for developability and clinical success. With over 140 partnerships, 650+ programs initiated, and 85+ clinical programs, Adimab has established a strong track record as a preferred partner for biologics discovery. The company offers flexible collaboration models, including funded discovery and platform transfer agreements.
Technology Platform
Proprietary yeast-based antibody discovery and engineering platform combining fully human synthetic and immune libraries for high-throughput screening and optimization of IgGs, HCAbs, multispecifics, TCRs, and other proteins, with a focus on developability.
Opportunities
Risk Factors
Competitive Landscape
Adimab competes with other antibody discovery platform companies using technologies like phage display (e.g., Dyax, now part of Takeda), mammalian display (e.g., Ablexis, now part of Ligand), and transgenic animals (e.g., Regeneron's VelocImmune). It also faces competition from large CROs offering discovery services and internal platforms at big pharma. Its key differentiators are its yeast-based eukaryotic system, integrated developability screening, and strong track record of clinical translation.